These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 165942)

  • 21. Quantitation of radio-ligand binding data using a desk-top calculator in the program mode.
    Brooks WF; Wittliff JL
    Anal Biochem; 1973 Aug; 54(2):464-76. PubMed ID: 4353365
    [No Abstract]   [Full Text] [Related]  

  • 22. Affinity of estradiol mustard for estrogen receptors and its enzymatic degradation in uterine and breast cancer cytosols.
    Leclercq G; Deboel MC; Heuson JC
    Int J Cancer; 1976 Dec; 18(6):750-6. PubMed ID: 992905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential for a novel pure anti-oestrogen.
    Wakeling AE
    Horm Res; 1989; 32 Suppl 1():257-9; discussion 260. PubMed ID: 2613211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
    Roos W; Oeze L; Löser R; Eppenberger U
    J Natl Cancer Inst; 1983 Jul; 71(1):55-9. PubMed ID: 6575210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of estradiol binding to human tissue proteins by unsaturated nonesterified fatty acids.
    Benassayag C; Vallette G; Hassid J; Raymond JP; Nunez EA
    Endocrinology; 1986 Jan; 118(1):1-7. PubMed ID: 3940850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer.
    Siiteri PK; Schwarz BE; MacDonald PC
    Gynecol Oncol; 1974 Aug; 2(2-3):228-38. PubMed ID: 4376104
    [No Abstract]   [Full Text] [Related]  

  • 27. Content of estrogen receptors in human breast cancer.
    Spaeren U; Olsnes S; Brennhovd I; Efskind J; Pihl A
    Eur J Cancer (1965); 1973 May; 9(5):353-7. PubMed ID: 4355726
    [No Abstract]   [Full Text] [Related]  

  • 28. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
    Parisot JP; Leeding KS; Hu XF; DeLuise M; Zalcberg JR; Bach LA
    Breast Cancer Res Treat; 1999 Jun; 55(3):231-42. PubMed ID: 10517168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Geometric isomers of substituted triphenylethylenes and antiestrogen action.
    Jordan VC; Haldemann B; Allen KE
    Endocrinology; 1981 Apr; 108(4):1353-61. PubMed ID: 6781873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of immunoassayable estrogen receptor lacking hormone binding ability in tamoxifen-treated rat uterus.
    Nakao M; Sato B; Koga M; Noma K; Kishimoto S; Matsumoto K
    Biochem Biophys Res Commun; 1985 Oct; 132(1):336-42. PubMed ID: 3904747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor. Therapeutic guide in undifferentiated metastatic carcinoma in women.
    Golomb HM; Thomsen S
    Arch Intern Med; 1975 Jul; 135(7):942-5. PubMed ID: 168822
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of tritiated estradiol and tamoxifen aziridine for measurement of estrogen receptors in human breast cancer cytosols.
    Piccart MJ; Muquardt C; Bosman C; Pirotte P; Veenstra S; Grillo F; Leclercq G
    J Natl Cancer Inst; 1991 Nov; 83(21):1553-9. PubMed ID: 1960752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A thin-layer gel filtration assay of cytoplasmic oestrogen receptors. A possible screening method for hormone dependent tumours.
    Gore-Langton RE; Ashwood-Smith MJ; Algard FT; van Netten JP
    Br J Cancer; 1973 Oct; 28(4):310-5. PubMed ID: 4357271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Speculation on the mechanism of action of triphenylethylene antioestrogens.
    van den Koedijk CD; Blankenstein MA; Thijssen JH
    Biochem Pharmacol; 1994 Jun; 47(11):1927-37. PubMed ID: 8010979
    [No Abstract]   [Full Text] [Related]  

  • 35. Specific estrogen-binding capacity of the cytoplasmic receptor in normal and neoplastic breast tissues of humans.
    Wittliff JL; Hilf R; Brooks WF; Savlov ED; Hall TC; Orlando RA
    Cancer Res; 1972 Sep; 32(9):1983-92. PubMed ID: 4345046
    [No Abstract]   [Full Text] [Related]  

  • 36. Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells.
    Hochner-Celnikier D; Greenfield C; Finci-Yeheskel Z; Milwidsky A; Gutman A; Goldman-Wohl D; Yagel S; Mayer M
    Mol Hum Reprod; 1997 Dec; 3(12):1019-27. PubMed ID: 9464846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The competitive relations of tamoxifen and estradiol at the level of the plasma membranes of the target cells].
    Mineeva EN
    Farmakol Toksikol; 1990; 53(6):26-7. PubMed ID: 2081562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Steroid hormone receptors in normal uterine endometrium and uterine adenocarcinoma of human subjects (author's transl)].
    Nioka S
    Nihon Naibunpi Gakkai Zasshi; 1978 Feb; 54(2):158-73. PubMed ID: 640096
    [No Abstract]   [Full Text] [Related]  

  • 39. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers.
    Van Aswegen CH; Purdy RH; Wittliff JL
    J Steroid Biochem; 1989 Apr; 32(4):485-92. PubMed ID: 2542691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.